FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285093622> ?p ?o ?g. }

• W4285093622 endingPage "3847" @default.
• W4285093622 startingPage "3839" @default.
• W4285093622 abstract "PURPOSE Metastatic retinoblastoma has a poor prognosis when treated with conventional chemotherapy and radiation therapy (RT). Intensified therapy may improve the outcome. METHODS A prospective, international trial enrolled patients with extraocular retinoblastoma. Patients with stage II or III (locoregional) retinoblastoma received four cycles of chemotherapy, followed by involved field RT (45 Gy). Patients with stage IVa or IVb (metastatic or trilateral) retinoblastoma also received four cycles of chemotherapy and those with ≥ partial response then received one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support. Patients with stage IVa or IVb with residual tumor postchemotherapy received RT. The proportion of patients who achieved event-free survival would be reported and compared with historical controls separately for each of the three groups of patients. RESULTS Fifty-seven eligible patients were included in the analyses. Event-free survival at 1 year was 88.1% (90% CI, 66.6 to 96.2) for stage II-III, 82.6% (90% CI, 61.0 to 92.9) for stage IVa, and 28.3% (90% CI, 12.7 to 46.2) for stage IVb/trilateral. Toxicity was significant as expected and included two therapy-related deaths. CONCLUSION Intensive multimodality therapy is highly effective for patients with regional extraocular retinoblastoma and stage IVa metastatic retinoblastoma. Although the study met its aim for stage IVb, more effective therapy is still required for patients with CNS involvement (ClinicalTrials.gov identifier: NCT00554788 )." @default.
• W4285093622 created "2022-07-14" @default.
• W4285093622 creator A5006930070 @default.
• W4285093622 creator A5019581189 @default.
• W4285093622 creator A5020074136 @default.
• W4285093622 creator A5021052212 @default.
• W4285093622 creator A5022440125 @default.
• W4285093622 creator A5032013913 @default.
• W4285093622 creator A5032519145 @default.
• W4285093622 creator A5040421529 @default.
• W4285093622 creator A5047847872 @default.
• W4285093622 creator A5051711134 @default.
• W4285093622 creator A5053244337 @default.
• W4285093622 creator A5068118481 @default.
• W4285093622 creator A5083288793 @default.
• W4285093622 creator A5087593086 @default.
• W4285093622 creator A5090325707 @default.
• W4285093622 date "2022-11-20" @default.
• W4285093622 modified "2023-09-29" @default.
• W4285093622 title "Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321)" @default.
• W4285093622 cites W1832098425 @default.
• W4285093622 cites W1865184513 @default.
• W4285093622 cites W1963916172 @default.
• W4285093622 cites W1966639599 @default.
• W4285093622 cites W1978224507 @default.
• W4285093622 cites W1979208346 @default.
• W4285093622 cites W2001790441 @default.
• W4285093622 cites W2003632365 @default.
• W4285093622 cites W2019825984 @default.
• W4285093622 cites W2039334526 @default.
• W4285093622 cites W2049616201 @default.
• W4285093622 cites W2065547319 @default.
• W4285093622 cites W2075496441 @default.
• W4285093622 cites W2078591757 @default.
• W4285093622 cites W2094540029 @default.
• W4285093622 cites W2106382582 @default.
• W4285093622 cites W2321013488 @default.
• W4285093622 cites W2759328813 @default.
• W4285093622 doi "https://doi.org/10.1200/jco.21.02337" @default.
• W4285093622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35820112" @default.
• W4285093622 hasPublicationYear "2022" @default.
• W4285093622 type Work @default.
• W4285093622 citedByCount "9" @default.
• W4285093622 countsByYear W42850936222022 @default.
• W4285093622 countsByYear W42850936222023 @default.
• W4285093622 crossrefType "journal-article" @default.
• W4285093622 hasAuthorship W4285093622A5006930070 @default.
• W4285093622 hasAuthorship W4285093622A5019581189 @default.
• W4285093622 hasAuthorship W4285093622A5020074136 @default.
• W4285093622 hasAuthorship W4285093622A5021052212 @default.
• W4285093622 hasAuthorship W4285093622A5022440125 @default.
• W4285093622 hasAuthorship W4285093622A5032013913 @default.
• W4285093622 hasAuthorship W4285093622A5032519145 @default.
• W4285093622 hasAuthorship W4285093622A5040421529 @default.
• W4285093622 hasAuthorship W4285093622A5047847872 @default.
• W4285093622 hasAuthorship W4285093622A5051711134 @default.
• W4285093622 hasAuthorship W4285093622A5053244337 @default.
• W4285093622 hasAuthorship W4285093622A5068118481 @default.
• W4285093622 hasAuthorship W4285093622A5083288793 @default.
• W4285093622 hasAuthorship W4285093622A5087593086 @default.
• W4285093622 hasAuthorship W4285093622A5090325707 @default.
• W4285093622 hasConcept C104317684 @default.
• W4285093622 hasConcept C126322002 @default.
• W4285093622 hasConcept C141071460 @default.
• W4285093622 hasConcept C143998085 @default.
• W4285093622 hasConcept C146357865 @default.
• W4285093622 hasConcept C151730666 @default.
• W4285093622 hasConcept C185592680 @default.
• W4285093622 hasConcept C2776577112 @default.
• W4285093622 hasConcept C2776694085 @default.
• W4285093622 hasConcept C2776755627 @default.
• W4285093622 hasConcept C2778119113 @default.
• W4285093622 hasConcept C2778239845 @default.
• W4285093622 hasConcept C2779968505 @default.
• W4285093622 hasConcept C2781451048 @default.
• W4285093622 hasConcept C509974204 @default.
• W4285093622 hasConcept C55493867 @default.
• W4285093622 hasConcept C71924100 @default.
• W4285093622 hasConcept C86803240 @default.
• W4285093622 hasConceptScore W4285093622C104317684 @default.
• W4285093622 hasConceptScore W4285093622C126322002 @default.
• W4285093622 hasConceptScore W4285093622C141071460 @default.
• W4285093622 hasConceptScore W4285093622C143998085 @default.
• W4285093622 hasConceptScore W4285093622C146357865 @default.
• W4285093622 hasConceptScore W4285093622C151730666 @default.
• W4285093622 hasConceptScore W4285093622C185592680 @default.
• W4285093622 hasConceptScore W4285093622C2776577112 @default.
• W4285093622 hasConceptScore W4285093622C2776694085 @default.
• W4285093622 hasConceptScore W4285093622C2776755627 @default.
• W4285093622 hasConceptScore W4285093622C2778119113 @default.
• W4285093622 hasConceptScore W4285093622C2778239845 @default.
• W4285093622 hasConceptScore W4285093622C2779968505 @default.
• W4285093622 hasConceptScore W4285093622C2781451048 @default.
• W4285093622 hasConceptScore W4285093622C509974204 @default.
• W4285093622 hasConceptScore W4285093622C55493867 @default.
• W4285093622 hasConceptScore W4285093622C71924100 @default.
• W4285093622 hasConceptScore W4285093622C86803240 @default.
• W4285093622 hasIssue "33" @default.

• next